Anti-depressant-like activity of mucuna pruriens; a traditional Indian herb in rodent models of depression

Pharmacologyonline

Volumn 1, Issue , 2010, Pages 537-551

  Pati, Dipanwita ^a   Pandey, Dilip Kumar ^a   Mahesh, Radhakrishnan ^a   Kurdekar, Vadiraj ^a   Jhadav, Hemant R ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Anti depressant; Forced swim test; Mucuna pruriens; Olfactory bulbectomy; Reserpine

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMFEBUTAMONE; ESCITALOPRAM; FLUOXETINE; MUCUNA PRURIENS EXTRACT; PLANT EXTRACT; RESERPINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG POTENTIATION; FORCED SWIMMING TEST; HEAD TWITCH; HYPOTHERMIA; INDIA; MALE; MOUSE; NONHUMAN; OLFACTORY BULBECTOMY; OPEN FIELD TEST; RAT; SINGLE DRUG DOSE; TRADITIONAL MEDICINE; TREATMENT DURATION; VELVET BEAN;

EID: 77953220562     PISSN: None     EISSN: 18278620     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Schloss, P., Henm F. A. (2004) New insights into the mechanisms of antidepressant therapy. Pharmacol Ther, 102:47-60.
2. Kessler, R. C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K. R. (2003) National Comrobidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA, 289:3095-3105.
3. Nemeroff, C. B. (2007) The burden of severe depression: a review of diagnositic Challenges and treatment alternatives. J Psychiatr Res, 41:189-206.
4. Patten, S. B. (2008) Major depression prevalence is very high, but the syndrome is a poor proxy for community populations' clinical treatment needs. Can J Psychiatry 53:411-419.
5. Bidzinska, E. J. (1984) Stress factors in affective diseases. British Journal Psychiatry, 144:161-6.
6. Eley, T. C. (1999) Behavioral genetics as a tool for developmental psychology: anxiety and depression in children and adolescents. Clin Child Fam Psychol Rev2: 21-36.
7. Nestler, E. J., Barrot M., DiLeone R. J., Eisch A. J., Gold S. J., Monteggia L. M. (2002) Neurobiology of depression. Neuron 34:13-25.
8. Grippo, A. J., Beltz T. G., Johnson A. K. (2003) Behavioral and cardiovascular changes in the chronic mild stress model of depression. Physiol Behav, 78:703-710.
9. Irwin, M. R. (2008) Human psychoneuroimmunology: 20 years of discovery. Brain Behav 22:129-39.
10. Kennedy, S. H. (2006) A review of antidepressant treatments today. Eur Neuropsychopharmacol, 16: S19-623.
11. Tamminga, C. A., Nemeroff C. B., Blakely R. D., Brady L., Carter C. S., Davis K. L. (2002) Developing novel treatments for mood disorders: Accelerating discovery. Biol Psychiatry 52: 589-609.
12. Adell, A., Castro E., Celada P., Bortolozzi A., Pazos A., Artigas F. (2005). Strategies for producing faster acting antidepressants. Drug Discov Today, 10: 578-585.
13. Buckles, D. (1995) Velvet bean(Mucuna pruriens): A "new" plant with a history. Economic Botany 49(1): 13-25.
14. Katzenschlager, R., Evans A., Manson A. (2004) Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry, 75:1672-1677.
15. Vaidya, R. A., Allorkar S. D., Seth A. R and Panday S. K. (1978a) The inhibitory effect of Cowhage plant Mucuna pruriens and L-DOPA in chlorpromazine induced hyperprolacteinaemia in man. Neurol. India 26(4): 1778.
16. Vaidya, A. B., Rajagopalan T. G., Mankodi N. A., Antarkar D. S., Tathed P. S., Purohit A. V. (1978b) Treatment of Parkinson's disease with the cowhage plant-Mucuna pruriens Bak. Neurol. India 26(4): 171-176.
17. Rajeshwar, Y., Gupta M., Mazumder U. K. (2005) Antitumour activity and in vitro antioxidant status of Mucuna pruriens (Fabaceae) against Ehrlich Ascites Carcinoma in Swiss Albino Mice. Iranian Journal of pharmacology & Therapeutics, 4(1): 46-53.
18. Manyam, B. V., Dhanasekaran M., Hare T. A. (2004) Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytother. Res, 18(9): 706-712.
19. Tripathi, Y. B., Upadhyay A. K. (2001) Antioxidant property of Mucuna pruriens Linn. Current Science, 80(11): 1378.
20. Poornachandra, M. N., Khanam S., Shivananda B. G., Shivananda T. N., Dris R. (2005) Mucuna pruriens (L.) DC-A novel drug for learning and memory retrieval. Journal of Food, Agriculture & Environment 3: 13-15.
21. Bell, E. A., Janzen D. H. (1971) Medical and ecological considerations of L-Dopa and 5-HTP in seeds. Nature, 229: 136-137.
22. Daxenbichler, M. E., VanEtten C. H., Hallinan, E. A., Earle F. R., (1971) Barclay A. S. Seeds as sources of L-dopa. Journal of Medicinal Chemistry, 14: 463-465.
23. Duke. Phytochemical database, Available at: http://www.raintree.com/db/Mucuna-pruriens-phytochem.htm. Accessed-January 10, 2007.
24. Parikh, K. M., Doshi V. J., Sawant S. V., Salunkhe U. B. (1990) Estimation of L-dopa from the plant Mucuna pruriens and its formulations using high performance liquid chromatography (HPLC). Indian Drugs 27: 353-356.
25. Rajagopal, V. Standardization of Botanicals (Eastern Publishers, New Delhi, 2002) p 92-99
26. Ramamoorthy, R., Radhakrishnan, M., Borah, M. (2008) Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models. Behav-Pharmacol.: 29-40
27. Boissier, J. R., Simon P. (1965). Action of caffeine on the spontaneous motility of the mouse. Arch. Int. Pharmacodyn. Ther, 158, 212-221.
28. Porsolt, R. D., Bertin A., Jalfre M. (1977) Behavioural despair in mice: a primary screening test for anti-depressants. Arch. Int. Pharmacodyn. Ther, 229: 327-336.
29. Steru, L., Chermat R., Thierry B., Simon P. (1985) The tail suspension test: a new method for screening anti-depressant drugs. Psychopharmacolgy, 85: 367-370.
30. Martin, P., Massol, J., Soubrie, P., Puech, A. J. (1989) Effects of triiodothyronine (T3) on the potentiation by antidepressants of L-5-hydroxytryptophan-induced head-twitches in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry: 735-748
31. Englert, L. F., Ho B. T., Taylor D. (1973) The effects of(-)-delta9-tetrahydrocannabinol on reserpine-induced hypothermia in rats. Br. J. Pharmacol 49: 243-252.
32. Mahesh, R., Rajkumar, R., Minasri, B., Venkatesha Perumal, R. (2007) Potential antidepressants: pharmacology of 2-(4-methylpiperazin-1-yl)-1, 8-naphthyridine-3-carbonitrile in rodent behavioral models. Pharmazie: 919-924
33. Kelly, J. P., Wyrnn, A. S., Leonard, B. E. (1997) Olfactory bulbectomized rat as a model of depression: an update. Pharmacol. Ther.: 299-316
34. Luo, L., Nong Wang J., Kong V., Jiang Q. G., Tan R. X. (2000) Anti-depressant effects of Banxia Houpu decoction, a traditional Chinese medicinal empirical formula. J Ethnopharmacol, 73: 277-281.
35. Kim, S. H., Han J., Seog D. H., Chung J. Y., Kim N., Hong Park. Y. (2005) Anti-depressant effect of Chaihu-Shugan-San extract and its constituents in rat models of depression. Life Sci, 23: 1297-1306.
36. Zhang, Y. Z., Nie H. M., Zhang D. C., He W., Fu Y. L. (2001) The behavioral pharmacology studies about Chaihu jia Longgu muli-tang and other classical prescriptions of traditional Chinese medicine, which are used to treat depressive disorder. Chin J Basic Med TCM (Chin) 510-512.
37. Sanchez-Mateo, C. C., Bonkanka C. X., Prado B., Rabanal R. M. (2005) Anti-depressant properties of some Hypericum canariense L. and Hypericum glandulosum Ait. extracts in the forced swimming test in mice. Journal of Ethnopharmacol, 97: 541-547.
38. Yu, Z. F., Kong L. D., Chen Y. (2002) Anti-depressant activity of aqueous extracts of Curcuma longa in mice. J Ethnopharmacol 83: 161-165.
39. Cryan, J. F., Valentino R. J., Lucki I. (2005) Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci. Biobehav. Rev, 9: 547-569.
40. Borsini, F., Meli A. (1988) Is the forced swimming test a suitable model for revealing anti-depressant activity? Psychopharmacology, 94; 147-160.
41. Pandey, D. K., Ramamoorthy R., Mahesh R., Radha R. (2008) Depressant-like effects of Parthenolide in rodent behavioural anti-depressant test battery. Journal of Pharmacy Phamacology, 60, 1643-1650.
42. Ortmann, R., Martin S., Radeke E., Delini Stula A. (1981) Interaction of beta-adrenoreceptor agonists with the serotonergic system in rat brain. A behavioural study using the L-5-HTP syndrome. Naunyn Schmiedeberg's Arch. Pharmacol, 316: 225-230.
43. 1A agonists. J. Pharmacol. Exp. Ther, 273, 101-112.
44. Lumia, A. R., Teicher M. H., Salchli F., Ayers E., Possidente B. (1992) Olfactory bulbectomy as a model for agitated hyposerotonergic depression. Brain Res, 587: 181-185.
45. Bourin, M., Fiocco A. J., Clenet F. (2001) How valuable are animal models in defining anti-depressant activity? Hum Psychopharmacol Clin, 16, 9-21.
46. Song, C., Leonard B. E. (2005) The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev, 29: 627-647.
47. Slotkin, T. A., Miller D. B., Fumagali F., Mccook E. C., Zhang J., Bissette G., Seidler F. J. (1999) Modeling geriatric depression in animals: biochemical and behavioural effects of olfactory bulbectomy in young versus aged rats. J Pharmacol Exp Ther, 289: 334-345.
48. Van Reizen, H., Leonard B. E. (1990) Effects of psychotropic drugs on the behaviour and neurochemistry of olfactory Bulbectomised rats. Pharmacol Ther, 47: 21-34.
49. Schafer, W. R. (1999) How do anti-depressant work? Prospect for genetic analysis of drug mechanism. Cell, 98: 551-554.